19 registrations that name octreotide as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 19 registrations
Status
Phase
22US sites across 15 states
1
2 to 4
5 to 19
20 or more
All 19 registrations
RecruitingNCT06784752
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
Phase 3
Novartis Pharmaceuticals
About 240 people
Started May 30, 2025
In plain words A Phase 3 study of octreotide in people 12 to 100, run by Novartis Pharmaceuticals. It plans to enroll about 240 people at 67 sites, 20 of them in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 12 to 100. Conditions: Somatostatin Receptor Positive (SSTR+); Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET).
Presence of metastasized or locally advanced, unresectable (curative intent), histologically proven, well differentiated Grade 1 or Grade 2 (Ki-67 <10%) gastroenteropancreatic neuroendocrine tumor (GEP-NET) diagnosed within 6 months prior…
Participants with high disease burden in the Investigator's opinion. Following criteria should be used as the guiding principle for determining high disease burden:
Primary tumor or a metastatic lesion > 4 cm
More than one tumor or metastatic lesions measuring > 2 cm
22 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
[177Lu]Lu-DOTA-TATE; Octreotide LAR
Registered summary
The purpose of the current study is to evaluate the efficacy and safety of \[177Lu\]Lu-DOTA-TATE plus octreotide long-acting release (LAR) versus octreotide LAR alone in newly diagnosed patients with somatostatin receptor positive (SSTR+), well differentiated Grade1 and Grade 2 (G1 and G2) (Ki-67 \<10%) advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) with high disease burden
Where, as registered
20 US sites in 14 states; also Italy (8), Spain (7), France (6), Poland (6), Canada (4), China (4), Germany (3), South Korea (3), Hungary (2), Netherlands (2), United Kingdom (2).
RecruitingNCT07255248
Hoffa's Fat Pad Impingement (HFPI)
Phase 4
Boston Children's Hospital
About 62 people
Started Mar 1, 2026
In plain words A Phase 4 study of octreotide in female participants 12 to 18, run by Boston Children's Hospital. It plans to enroll about 62 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists female participants 12 to 18. Conditions: Hoffa's Fat Pad Impingement.
Clinical diagnosis of HFPI (defined as pain to palpation over the medial or lateral aspect of the infrapatellar fat pad, and/or positive hoffa test which is performed by exerting direct pressure over the infrapatellar fat pad as the knee…
Age 12-18 years
Patients who identify as female
Organized sports participation is defined as any adult-led game or sport in which three or more people play and/or practice together regularly in a league or association or an adult-led individual athletic activity.
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
methylprednisolone acetate and lidocaine; Saline injection (Octreotide LAR placebo)
Registered summary
The aim of the study is to investigate treatment outcomes for refractory anterior knee pain due to Hoffa's Fat Pad Impingement (HFPI) in young female athletes. Specifically, the study team will study pediatric female athletes with HFPI, and treatment outcomes of US-guided Hoffa's Fat Pad (HFP) corticosteroid injection compared to standard care (physical therapy, bracing, no injection) and saline injection. There will be two arms in this study, 1, a corticosteroid injection and physical therapy and 2, physical therapy and a saline injection. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT03158090
The Longitudinal Approach to Acromegaly: A Pattern of Treatment and Comparative Effectiveness Research
Observational
Ginkgo Leaf Center for Rare Disorders
About 1,965 people
Started Dec 15, 2017
In plain words An observational study of octreotide in people 18 to 75, run by Ginkgo Leaf Center for Rare Disorders. It plans to enroll about 1,965 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 75. Conditions: Acromegaly.
Be able and willing to sign the informed consent form (ICF)
Male, female, age 18-75 years old (including 18 years old and 75 years old).
Compliance with acromegaly diagnostic criteria:
At least one laboratory or medical record shows that the patient is random GH ≥ 2.5 μg / L
1 more inclusion criterion and the exclusion criteria are on the listing.
This study is a prospective, noninteractive, observational, and longitudinal study aimed at assessing the treatment pattern and clinical outcome of acromegaly in China.
Where, as registered
No US site; China (1).
RecruitingNCT05749289
Application of Al18F-octreotide PET/CT in Tumors With Positive SSTR Expression
Phase 2 and 3
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
About 400 people
Started Dec 20, 2022
In plain words A Phase 2 and 3 study of octreotide in people 18 and older, run by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. It plans to enroll about 400 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: SSTR Positive Tumors.
Patients with suspected or clearly diagnosed SSTR positive tumors
signed written consent.
Willing and able to cooperate with all projects in this study.
The exclusion criteria are on the listing.
What it tests, as registered
Al18F-octreotide
Registered summary
This is an open-label whole-body PET/CT study for investigating the value of Al18F-octreotide PET/CT in patients with SSTR positive tumors
Where, as registered
No US site; China (1).
RecruitingNCT07262957
Preventing Postoperative Complications in Patients Undergoing High-risk Pancreatoduodenectomy With a Bundle Approach Including Hydrocortisone, Octreotide, and the Teres Ligament Patch (PANENCA)
Phase 4
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
About 400 people
Started Sep 1, 2025
In plain words A Phase 4 study of octreotide in people 18 and older, run by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA). It plans to enroll about 400 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Pancreas Head Cancer; Pancreas Adenocarcinoma; IPMN, Pancreatic; Cholangio Carcinoma; Ampulla of Vater Adenocarcinoma; PDAC - Pancreatic Ductal Adenocarcinoma; Duodenal Carcinoma; Mucinous Cystic Neoplasm; Neuro Endocrine Tumours; Pancreatitis.
Elective pancreatoduodenectomy for any indication (both minimally invasive and open)
Pancreatic duct diameter ≤ 3mm on preoperative CT or MRI*
18 years of age or older
Signature of informed consent
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
HOP bundle
Registered summary
The PANENCA trial aims to reduce postoperative complications in patients undergoing pancreatoduodenectomy (also known as a Whipple procedure), a complex surgical operation performed to remove tumors located in or near the head of the pancreas. One of the most frequent and serious complications after this surgery is postoperative pancreatic fistula (POPF), a leakage of pancreatic fluid from the surgical connection. POPF can lead to intra-abdominal infection, bleeding, and inflammation, often resulting in delayed recovery and postponement of subsequent oncological treatment. The full summary is on the listing.
Where, as registered
No US site; Netherlands (1).
RecruitingNCT07165886
Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors
Phase 2 and 3
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
About 298 people
Started Aug 29, 2025
In plain words A Phase 2 and 3 study of octreotide in people 18 and older, run by CSPC ZhongQi Pharmaceutical Technology Co., Ltd.. It plans to enroll about 298 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Gastroenteropancreatic Neuroendocrine Tumors.
1\. Unresectable locally advanced or metastatic G1/G2 GEP-NETs diagnosed by histology, according to the 2019 WHO histological grading criteria.
2\. Having poor prognostic factors.
3\. Non-functional GEP-NETs are required.
4\. At least one evaluable lesion meets the RECIST V1.1 standard (Applicable only to the phase II safety run-in stage)
3 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Sirolimus for injection (albumin bound); Octreotide long-acting injection; Everolimus
Registered summary
There is limited evidence regarding the benefit of adding somatostatin analogs to molecular targeted agents for well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs) with poor prognostic factors. This trial is conducted to evaluate sirolimus for injection (albumin bound) combined with octreotide long-acting injection in patients with unresectable or recurrent GEP-NETs.
Where, as registered
No US site; China (1).
RecruitingNCT05701241
Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients
Phase 4
University Hospital, Antwerp
About 270 people
Started Jun 28, 2023
In plain words A Phase 4 study of octreotide in people 18 and older, run by University Hospital, Antwerp. It plans to enroll about 270 people at 19 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Gastroenteropancreatic Neuroendocrine Tumor.
Age ≥18 years
Written informed consent prior to any study-related procedures
Eastern Cooperative Oncology Group (ECOG) performance status ≤2,
Histologically-proven diagnosis of locally advanced or metastatic, non-functional, well-differentiated World Health Organisation 2019 grade 1-2 GEP NET
3 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Somatostatin analog
Registered summary
The SAUNA trial is a multi-national, multi-centre, open-label, randomised, controlled, pragmatic clinical trial in patients with advanced, non-functional gastroenteropancreatic (GEP) neuroendocrine tumours (NET) with progressive disease on first-line therapy with somatostatine analogues (SSA). Eligible patients will be divided into two substudies according to the second-line therapy of choice (peptide receptor radionuclide therapy (PRRT) or targeted therapy, at the discretion of the local investigator). The full summary is on the listing.
Where, as registered
No US site; Belgium (13), Netherlands (6).
RecruitingNCT05884255
An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.
Phase 3
Jiangsu HengRui Medicine Co., Ltd.
About 220 people
Started Jul 6, 2023
In plain words A Phase 3 study of octreotide in people 18 to 75, run by Jiangsu HengRui Medicine Co., Ltd.. It plans to enroll about 220 people at 2 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 75. Conditions: Advanced Gastroenteropancreatic Neuroendocrine Tumor.
Able and willing to provide a written informed consent;
18~75 years old,male or female;
ECOG performance status 0 or 1;
Unresectable locally advanced or metastatic gastrointestinal neuroendocrine tumors (GEP-NETs) of low and medium grade (G1 or G2) confirmed by histopathology.
The study is being conducted to evaluate the efficacy, and safety of Lutetium (177Lu) Oxodotreotide Injection in subjects with advanced gastrointestinal pancreatic neuroendocrine tumors.
Where, as registered
No US site; China (2).
RecruitingNCT07583563
An Observational Study of Octreotide Subcutaneous Depot in Patients With Acromegaly
Observational
Camurus AB
About 200 people
Started Jun 5, 2026
In plain words An observational study of octreotide in people 18 and older, run by Camurus AB. It plans to enroll about 200 people at 6 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Acromegaly.
Have started or will be starting treatment with octreotide SC depot for acromegaly
The exclusion criteria are on the listing.
What it tests, as registered
Octreotide subcutaneous depot
Registered summary
The purpose of this study is to collect long-term (up to two years) safety and effectiveness of octreotide subcutaneous depot in patients with acromegaly in the real-world setting.
Where, as registered
No US site; Germany (5), United Kingdom (1).
RecruitingNCT07057622
A Phase III Clinical Study to Compare the Safety and Efficacy of 177Lu-DOTATATE Injection and Long-acting Oxytrexine in Adult Patients With NETs
Phase 3
HTA Co., Ltd.
About 184 people
Started Dec 12, 2023
In plain words A Phase 3 study of octreotide in people 18 and older, run by HTA Co., Ltd.. It plans to enroll about 184 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: NETS Ga68 Lu177.
Ability to understand and the willingness to sign a written informed consent document;
Age ≥18 years ;
Low-and medium-grade ( G1 or G2) unresectable locally advanced or metastaticgastrointestinalneuroendocrine tumors(GEP-NETs)confirmed by histopatholog in the central laboratory,and those who had previously progressed after standard-dose…
Somatostatin receptor positive patients must be defined as all target lesions at baseline confirmed by PET/ CT examination of gallium \[68Ga\] dobutamine injection as somatostatin receptor positive(IRC confirmed);
4 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
177Lu-DOTATATE injection; Octreotide LAR (Long-acting release)
Registered summary
The study is to evaluate the sstr antagonists, 68Ga-DOTATATE and 177Lu-DOTATATE,as a pair of diagnostic/therapeuticradiopharmaceuticals(theranostics)in patients with NETS
Where, as registered
No US site; China (1).
RecruitingNCT06878664
Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors
Phase 3
Grupo Espanol de Tumores Neuroendocrinos
About 166 people
Started Jun 12, 2025
In plain words A Phase 3 study of octreotide in people 18 and older, run by Grupo Espanol de Tumores Neuroendocrinos. It plans to enroll about 166 people at 21 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Grade1-2 Advanced Midgut Neuroendocrine Tumors (NETs).
Patients who have histologically confirmed diagnosis of unresectable, advanced or metastatic midgut NETs (originated in the jejunum-ileum or right colon) who are candidates to receive 177Lu-Dotatate targeted radioligand therapy (RLT) and…
Ki-67 index ≤ 20%.
Disease progression per RECIST v1.1 within 36 months prior to study entry,
Patients may be treatment naïve (first-line) or have received prior systemic therapy except for any type of prior RLT (not restricted to 177Lu-Dotatate).
18 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
177Lu-Dotatate (7.4 Gigabecquerel/cycle) during 30 min intravenous infusion every 16 weeks (q8w) x 4 cycles; 2) and 3) as in the experimental arm.; 177Lu-Dotatate (7.4 Gigabecquerel/cycle) during 30 min intravenous infusion every 8 weeks (q8w) x 4 cycles; 2) and 3) as in the experimental arm.; Amino acid solution; Lanreotide (Autogel formulation) or Octreotide LAR
Registered summary
This is a randomized Phase II/late phase I de-escalation clinical trial with approved investigational medicinal products in new use condition, low intervention. Disease under study Patients with unresectable or metastatic, slowly progressive, well-differentiated (Grade1 and Grade2), somatostatin receptor-positive midgut neuroendocrine tumors (GEP-NETs). It is planned to randomize 166 patients with a histologically confirmed diagnosis of slowly progressive grade 1 or grade 2 advanced midgut neuroendocrine tumors (NETs) candidates to receive 177Lu-Dotatate targeted radioligand therapy (RLT). The full summary is on the listing.
Where, as registered
No US site; Spain (12), France (9).
RecruitingNCT06326190
177Lu-DOTATATE for Recurrent Meningioma
Phase 2
European Organisation for Research and Treatment of Cancer - EORTC
About 136 people
Started Mar 10, 2025
In plain words A Phase 2 study of octreotide in people 18 and older, run by European Organisation for Research and Treatment of Cancer - EORTC. It plans to enroll about 136 people at 19 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Recurrent Meningioma.
Adult patient ≥ 18 years of age
Histologically confirmed diagnosis of meningioma (all grades, 1-3 per WHO CNS5, are eligible)
WHO performance status 0-2
Measurable disease (at least 10 x10 mm contrast enhancing lesion) on cranial MRI no more than two weeks prior to randomization
10 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Local standard of Care; 177Lu-DOTATATE
Registered summary
Novel treatments are urgently needed for meningiomas progressing after local therapies (surgery, radiotherapy). So far, no effective systemic therapies are known in this situation. The LUMEN-1 trial will investigate in a prospective randomized trial the efficacy of the precision medicine "theranostic" concept of combining diagnostic patient selection using PET-based molecular imaging and target-specific therapeutic intervention using a systemically administered radioligand. The full summary is on the listing.
Where, as registered
No US site; France (7), Germany (4), Austria (2), Norway (2), Spain (2), Switzerland (2).
RecruitingNCT04917484
Dosimetry Based PRRT Versus Standard Dose PRRT With Lu-177-DOTATOC in NEN Patients
Phase 2
Tine Gregersen, MD
About 100 people
Started Feb 1, 2020
In plain words A Phase 2 study of octreotide in people 18 and older, run by Tine Gregersen, MD. It plans to enroll about 100 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Neuroendocrine Neoplasm.
1\. Male or female patients 18 years of age or more
2\. NEN confirmed by histology
3\. Clinical, PET/CT or CT proven progression despite standard treatment with somatostatin analogues, targeted therapy (Everolimus, sunitinib), chemotherapy (STZ/5-FU, temozolomide/capecitabine) OR intolerable side effects caused by these…
4\. WHO/ ECOG Performance Status of 0-2
9 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Lu-177-DOTA-Octreotide
Registered summary
In this study, we want to randomize patients with neuroendocrine neoplasms (NENs) who are eligible for peptide receptor radionuclide therapy (PRRT), to either standard PRRT consisting of 4 treatments with 7.4 GBq Lu-177-DOTATOC (standard arm) or 4 treatments with individualized doses of Lu-177-DOTATOC (dosimetry arm). In the dosimetry arm, the first dose depends on the patients' kidney function and thereafter the absorbed dose to the kidneys at the previous treatment. A max of 20GBq will be administered at the first treatment and 25GBq at treatment 2-4. The full summary is on the listing.
Where, as registered
No US site; Denmark (1).
RecruitingNCT06505395
A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET)
Phase 2
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
About 90 people
Started Jul 30, 2024
In plain words A Phase 2 study of octreotide in people 18 and older, run by CSPC ZhongQi Pharmaceutical Technology Co., Ltd.. It plans to enroll about 90 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Gastrointestinal Neuroendocrine Pancreatic Tumor.
Male or female patient ≥18 years old;
Histologically confirmed, advanced GEP-NET;
At least 1 measurable, somatostatin receptor-positive lesion according to RECIST 1.1;
Previous treatment with ≤2 systemic antitumor drugs;
5 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
SYHX2008 injection; Sandostatin LAR@
Registered summary
The purpose of this study is to compare the effectiveness, safety, pharmacokinetics (PK) of SYHX2008 vs Octreotide Microspheres (Sandostatin LAR@) in patients with advanced, well-differentiated GEP-NET.
Where, as registered
No US site; China (1).
Not yet recruitingNCT06558422
Human Models of Selective Insulin Resistance: Pancreatic Clamp
Phase 1
Columbia University
About 36 people
Starts Jan 1, 2027 (estimated)
In plain words A Phase 1 study of octreotide in people 18 to 65, run by Columbia University. It plans to enroll about 36 people at 1 US site.
This is a single-center, prospective, randomized, controlled (crossover) clinical study designed to investigate the impact of lowering insulin levels on hepatic glucose production (HGP) vs de novo lipogenesis (DNL) in people with insulin resistance. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
Not yet recruitingNCT06300216
A Real-world Study of Octreotide Microspheres in Chinese Patients With Neuroendocrine Tumors
Observational
Qilu Hospital of Shandong University
About 500 people
Starts Mar 26, 2024 (estimated)
In plain words An observational study of octreotide in people 18 and older, run by Qilu Hospital of Shandong University. It plans to enroll about 500 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Neuroendocrine Tumors.
Sign an informed consent form and voluntarily participate in this study;
Patients with unresectable or metastatic neuroendocrine tumors confirmed by histopathology. Patients with recurrence and progression after surgery or local treatment can also be included in the study;
Age ≥ 18 years old;
Treatment with octreotide microspheres.
The exclusion criteria are on the listing.
What it tests, as registered
Octreotide microspheres
Registered summary
The aim of this multicenter, open-label, observational study is to evaluate the safety and efficacy of octreotide microspheres in the treatment of advanced neuroendocrine tumors in real clinical practice, especially to evaluate the treatment of octreotide microspheres in various subgroups of neuroendocrine tumor patients.
Where, as registered
No US site; China (1).
Not yet recruitingNCT07479784
Octreotide Microspheres for Preventing Pancreatic Fistula
Phase 3
Shanghai Zhongshan Hospital
About 230 people
Starts Apr 1, 2026 (estimated)
In plain words A Phase 3 study of octreotide in people 18 to 80, run by Shanghai Zhongshan Hospital. It plans to enroll about 230 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 80. Conditions: Pancreatic Fistula.
Subjects voluntarily participate in this study and sign the informed consent form;
Age ≥18 and ≤80 years old, both males and females are eligible;
Preoperative imaging assessment indicates the corresponding disease is surgically resectable;
Planned to undergo distal pancreatectomy;
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Octreotide Microspheres; Placebo
Registered summary
This study is a randomized, double-blind, placebo-controlled, multicenter phase III clinical trial designed to evaluate the efficacy and safety of octreotide microspheres in preventing pancreatic fistula after distal pancreatectomy.
Where, as registered
No sites listed yet.
Not yet recruitingNCT07623824
A Phase III Clinical Trial to Evaluate the Efficacy and Safety of Octreotide Long-acting Injection in Patients With Acromegaly
Phase 3
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
About 154 people
Starts May 31, 2026 (estimated)
In plain words A Phase 3 study of octreotide in people 18 to 80, run by CSPC ZhongQi Pharmaceutical Technology Co., Ltd.. It plans to enroll about 154 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 80. Conditions: Diagnosed With Acromegaly, Currently in the Active Stage of the Disease.
Male or female participants aged 18 to 80 years (including boundary values)
Diagnosed with acromegaly, currently in the active stage of the disease (for patients who have not undergone pituitary tumor surgery before, MRI shows a pituitary mass, fasting GH ≥ 2.5 ng/mL and IGF-1 index ≥ 1.3; for patients who have…
The exclusion criteria are on the listing.
What it tests, as registered
SYHX2008; Sandostatin LAR®
Registered summary
he purpose of this study is to evaluate the efficacy and safety of SYHX2008 injection in in patients with acromegaly.
Where, as registered
No sites listed yet.
Not yet recruitingNCT06974344
Octreotide vs. Splenic Artery Ligation for Portal Flow Modulation in Living Donor Liver Transplants (SCALOP Trial)
Phase 4
King Faisal Specialist Hospital & Research Center
About 80 people
Starts Jun 1, 2025 (estimated)
In plain words A Phase 4 study of octreotide in people 18 to 70, run by King Faisal Specialist Hospital & Research Center. It plans to enroll about 80 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 70. Conditions: Small-for-Size Syndrome.
Age ≥ 18 and <70 years
Male and female genders
Undergoing Living Donor Liver Transplant (LDLT)
All indications
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Octreotide (drug); Splenic Artery Ligation (SAL)
Registered summary
The goal of this clinical trial is to compare two treatments for regulating blood flow in small liver grafts during living donor liver transplantation (LDLT). The main questions it aims to answer are: * Is octreotide (a medication) as effective or better than splenic artery ligation (surgery) in reducing complications after transplantation? * Which treatment better controls blood flow while causing fewer side effects? Researchers will compare octreotide (given through an IV) to splenic artery ligation (performed during surgery) to see which approach works best for patients receiving small… The full summary is on the listing.